Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. (PACB) develops long‑read DNA sequencing systems and consumables used in genomics research and translational science. Its platforms produce high‑accuracy long reads that help assemble complex genomes, call structural variants and support applications across human genetics, agricultural genomics and drug discovery. Revenue is driven by sales of instruments, recurring consumables, service agreements and software. With a market capitalisation of about $570.70m, PACB is a small‑cap, growth‑oriented company and its shares can be volatile. Key considerations for investors include product adoption, the recurring consumable revenue stream, competitive dynamics with short‑ and long‑read sequencing rivals, and the company’s pathway to sustainable profitability. Operational risks include execution on commercial roll‑out, supply‑chain constraints and R&D outcomes. This is general educational information only and not personal investment advice; values can rise and fall and past performance does not predict future returns.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Pacific Biosciences' stock with a target price of $2.25, indicating potential growth.
Financial Health
Pacific Biosciences is generating steady revenue and cash flow, but faces challenges in profitability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PACB
Activist Sparks Life Science Shakeup
Activist investor Engine Capital is pushing for a sale of life-sciences company Avantor after taking a significant stake. This move could spark a wave of M&A across the life-sciences supply industry, creating opportunities for competitor firms and other potential acquisition targets.
Published: August 11, 2025
Explore BasketPharma's American Reshoring Wave
AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
Published: July 23, 2025
Explore BasketDiagnostic Takeover Targets
This carefully selected group of stocks features innovative diagnostic companies that could become acquisition targets following recent takeover interest in the sector. Professional analysts have identified these companies for their unique technologies and established market positions in a consolidating healthcare landscape.
Published: July 15, 2025
Explore BasketSynthetic-Bio Foundries
Discover companies that are programming living cells to create the materials of tomorrow. These carefully selected stocks represent pioneers in replacing petrochemical processes with cleaner, more efficient biological alternatives - essentially turning microbes into tiny manufacturing plants.
Published: June 17, 2025
Explore BasketPatient Platforms
This carefully curated collection features companies building the technological foundations that will power innovation for decades to come. Our analysts have identified businesses creating essential infrastructure in genomics, AI, robotics, and advanced computing—platforms that could define their industries and generate substantial long-term returns.
Published: June 17, 2025
Explore BasketDeep Future
This collection features companies pioneering revolutionary technologies that could transform our world in the decades ahead. Carefully selected by our analysts, these stocks represent visionary enterprises working on quantum computing, next-generation energy, and genetic medicine breakthroughs.
Published: June 17, 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: May 6, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Long‑read sequencing
Unique long‑read technology can resolve complex genomic regions and structural variants, which attracts research and clinical interest — though adoption and commercial scale‑up can take time.
Product innovation
Newer, higher‑throughput systems aim to broaden addressable markets and improve per‑sample economics, but execution and competitive responses are important risks to monitor.
Research and markets
Used across human health, pharmaceuticals and agriculture, offering diverse end markets; revenues can be cyclical and are sensitive to institutional capital spending.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
